Cepheid (NASDAQ:CPHD) had its price objective raised by Raymond James from $43.00 to $50.00 in a research report released on Friday morning, AnalystRatingsNetwork.com reports. Raymond James currently has a buy rating on the stock.
Shares of Cepheid (NASDAQ:CPHD) traded up 1.59% during mid-day trading on Friday, hitting $44.72. 55,798 shares of the company’s stock traded hands. Cepheid has a one year low of $30.89 and a one year high of $44.63. The stock’s 50-day moving average is $40.3 and its 200-day moving average is $37.28. The company’s market cap is $3.034 billion.
Cepheid (NASDAQ:CPHD) last issued its quarterly earnings data on Thursday, October 17th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.09. The company had revenue of $100.10 million for the quarter, compared to the consensus estimate of $93.70 million. During the same quarter last year, the company posted ($0.32) earnings per share. Cepheid’s revenue was up 25.6% compared to the same quarter last year. On average, analysts predict that Cepheid will post $-0.22 earnings per share for the current fiscal year.
A number of other firms have also recently commented on CPHD. Analysts at Wedbush set a $47.00 price target on shares of Cepheid in a research note to investors on Wednesday, November 20th. They now have an outperform rating on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a neutral rating on shares of Cepheid in a research note to investors on Thursday, November 14th. They now have a $44.00 price target on the stock. Finally, analysts at UBS AG reiterated a buy rating on shares of Cepheid in a research note to investors on Sunday, November 3rd. They now have a $44.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. Cepheid presently has an average rating of Hold and an average price target of $43.03.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.